JM Financial has retained its Buy rating on Metropolis Healthcare with a target price of Rs 734, implying 27.2% upside. The brokerage calls it the cheapest among India’s leading listed diagnostic players, citing attractive valuations, network expansion, stronger B2C growth and improving margins as key drivers.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.